Natera Expands Lawsuit Against NeoGenomics to Include Additional Patent

MT Newswires Live
2024-12-17

Natera (NTRA) said Tuesday that it has expanded its patent infringement lawsuit against NeoGenomics (NEO) related to the latter's modified version of RaDaR tests for molecular residual disease.

Natera said the District Court for the Middle District of North Carolina has granted its request to include an additional patent as part of the lawsuit.

Natera is asking the court to award it full remedies against NeoGenomics' current RaDaR test offering, including injunctive relief.

NeoGenomics did not immediately respond to a request for comment from MT Newswires.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10